212127-80-5

Basic information

• Product Name: 2-(2,5-Dihydrofuran-3-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane
• Synonyms: ,5-dihydrofuranl-3-boronic ester;2-(2,5-Dihydrofuran-3-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane;(2,5-DIHYDROFURAN-3-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 212127-80-5
• Molecular Formula: C₁₀H₁₇BO₃
• Molecular Weight: 196.05118
• Product Categories: organic boroinic acid;Organic boronic acid
• Mol File: 212127-80-5.mol

Chemical Properties

• Boiling Point: 216.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.02±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 2-(2,5-Dihydrofuran-3-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,5-Dihydrofuran-3-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(212127-80-5)
• EPA Substance Registry System: 2-(2,5-Dihydrofuran-3-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane(212127-80-5)

Safety Data

• Hazardous Substances Data: 212127-80-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2,5-Dihydrofuran-3-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a key intermediate compound for the development of orally active Polo-like kinase-2 (Plk-2) inhibitors. These inhibitors are crucial in the treatment of various diseases, including cancer, due to their ability to target and inhibit the activity of Plk-2, a protein involved in cell division and regulation.
The compound is particularly valuable in the pharmaceutical industry because it serves as a building block for the synthesis of Plk-2 inhibitors, which have demonstrated potential in treating a range of diseases. By targeting Plk-2, these inhibitors can help regulate cell division and prevent the uncontrolled growth of cells, which is a hallmark of cancer.

Upstream product

• 212127-71-4 2-[3-(allyloxy)prop-1-en-2-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 1289181-57-2 (S)-2-(4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzylamino)-5-(2,5-dihydrofuran-3-yl)-N-(1-(4-fluorophenyl)ethyl)nicotinamide 
• 1613395-69-9 C₁₈H₂₀FN₃O₃ 

Relevant articles and documents

Multigram Synthesis of Heterabicyclo[n.1.0]alkan-1-yl Trifluoroborates

An approach to the synthesis of oxa- and azabicyclo[n.1.0]alkan-1-yl trifluoroborates on a multigram scale was developed. Two synthetic strategies were evaluated: the first based on the lithiation–borylation of the corresponding 2-bromoallyl derivatives, and the other relying on regioselective hydroboration of the appropriate hetera-substituted enynes. The second method appeared to be more efficient in terms of scalability and substrate scope. Further steps included ring closing-metathesis, mild palladium-catalyzed cyclopropanation with diazomethane, and reaction with KHF2 and furnished the title compounds in up to 50 g scale in a single run (10–41 % overall yield, 4–5 steps).

TYROSINE KINASE INHIBITORS

The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.